APixaban vs. PhenpRocoumon in Patients With ACS and AF: APPROACH-ACS-AF

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2016
It is hypothesised that a dual therapy strategy by oral anticoagulation with the new Factor-Xa-inhibitor apixaban plus clopidogrel is superior to a triple therapy regimen with phenprocoumon plus acetylsalicylic acid (ASA) and clopidogrel with respect to avoiding bleeding events in patients with atrial fibrillation undergoing percutaneous coronary intervention in the setting of an acute coronary syndrome.
Epistemonikos ID: 0a6c134bd958d4fa085858f4fa1ec6a0e1984022
First added on: May 17, 2024